News

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...
Becker's Hospital Review10h
Novartis gets FDA OK for 1st malaria drug for infants
The FDA has approved Novartis Coartem Baby, the first malaria treatment designed for newborns and young infants. The medicine, developed in collaboration with Medicines for Malaria Venture, a ...
BioSpace1d
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Wall Street Journal6d
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - WSJ - The Wall Street Journal
Regeneron on Wednesday said the FDA green light covers Lynozyfic in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a ...
He had six months to live. Then came an experimental cancer treatment launched by Harvard researchers.
The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.
Morningstar6d
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - Morningstar
Regeneron on Wednesday said the FDA green light covers Lynozyfic in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a ...
An Oklahoma family is on a mission to find a cure for a rare genetic disease. Here's how
Michael Gehr, of Edmond, and his family are on a mission to help find a cure for a rare genetic disease that he was diagnosed ...
Crews continue to scour Guadalupe River for flood victims
Thousands of first responders and volunteers are working tirelessly to recover victims of the deadly Texas Hill Country ...
Drug Store News21d
Azurity Pharmaceuticals obtains FDA OK for Xifyrm
Azurity Pharmaceuticals obtains FDA OK for Xifyrm Xifyrm is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics.
Congress needs to fix a policy that's blocking rare disease research | Opinion
Senators made the right decision for America's most vulnerable patients ― now, the House must follow suit. The ORPHAN Cures ...
McKnight's Long-Term Care News28d
Rare new antibiotic gets FDA OK for uncomplicated UTIs
The FDA has approved a new antibiotic that can treat uncomplicated urinary tract infections, or uUTIs. It’s the first new class of oral antibiotics for UTIs in almost 30 years, according to ...